World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 638-645

CLINICAL TRIALS IN MEDICAL DEVICES: REGULATORY, ETHICAL, AND METHODOLOGICAL FRAMEWORKS WITH A FOCUS ON DEEP BRAIN STIMULATION

Shravan K. Yadav*[1], Prof. Randhawan B.B.[2], Arya A. Shaligram[3], Nusratfatema K. Shaikh[4], Aarati B. Shinde[5]

[1,3,4,5]Students, Arihant College of Pharmacy, Kedgaon, Ahilyanagar – 414005.
[2]Assistant Professor, Arihant College of Pharmacy, Kedgaon, Ahilyanagar – 414005.

Article Received: 05 July 2025 | | ***Article Revised: 26 July 2025*** | | ***Article Accepted: 20 August 2025***

***Corresponding Author: Shravan K. Yadav**
Students, Arihant College of Pharmacy, Kedgaon, Ahilyanagar – 414005.
DOI: https://doi.org/10.5281/zenodo.17010855

How to cite this Article: Shravan K. Yadav, Prof. Randhawan B.B., Arya A. Shaligram, Nusratfatema K. Shaikh, Aarati B. Shinde (2025). CLINICAL TRIALS IN MEDICAL DEVICES: REGULATORY, ETHICAL, AND METHODOLOGICAL FRAMEWORKS WITH A FOCUS ON DEEP BRAIN STIMULATION. World Journal of Pharmaceutical Science and Research, 4(4), 638-645. https://doi.org/10.5281/zenodo.17010855

ABSTRACT

To ensure safety and efficacy, clinical trials for medical devices must adhere to stringent regulations, ethical standards, and rigorous scientific validation. Clinical trials for medical devices present unique challenges that are subject to thorough evaluation to ensure safety, efficacy, and regulatory compliance. This review describes the fundamental requirements for clinical trials involving medical devices, including regulatory frameworks, study design, and methodology. The essential requirements for clinical trials involving DBS (deep brain stimulation) devices include study design, patient selection criteria, ethical considerations, regulatory compliance, and risk management. Particular attention is paid to ethical issues like informed consent and patient safety, as well as the importance of interdisciplinary cooperation. Deep Brain Stimulation (DBS) is an advanced neuromodulation technique used to treat neurological illnesses such as Parkinson's disease, essential tremor, and dystonia. Conducting clinical trials for DBS devices involves particular problems because of their invasive nature, complex mechanism of action, and the necessity for long-term efficacy and safety studies. Medical device clinical trials verify that the items are made and designed in compliance with regulations. According to the conformance assessment, medical device manufacturers are primarily responsible for ensuring compliance with safety and performance requirements. Long-term follow-up, difficulties with placebo control, and device configuration are also covered. This study intends to aid in the creation of safe and efficient DBS treatments for neurological and psychiatric conditions by creating thorough criteria.

KEYWORDS: Clinical trials, DBS, medical devices, neurological, requirements.

INTRODUCTION

Medical Devices

- Any instrument, machine, contraption, implant, or in vitro reagent used for human or animal diagnostic and therapeutic purposes is considered a medical device, according to the US Food and Drug Administration (FDA).[1]
- According to the Indian government's regulations and regulatory body, a medical device is described as follows: Equipment that can be used either internally or externally to diagnose, treat, mitigate, or prevent diseases or disorders in humans or animals. Materials or equipment for in vitro diagnosis. Furthermore, surgical bandages, surgical sutures, surgical staples, surgical dressings, intrauterine devices, mechanical contraceptives, ligatures, insecticides, disinfectants, and bags for collecting blood and blood components are all regarded as medical devices.[2]
- The World Health Organization (WHO), on the other hand, defines a medical device as any tool, machine, appliance, or other item that is created by the manufacturer and intended for use for particular medical purposes, whose main function is not accomplished by immunological, metabolic, or pharmacological means.[1]
- A vital part of the healthcare system, medical devices are used to identify, treat, alleviate, or prevent illnesses.[2]

CLASSIFICATION OF MEDICAL DEVICES ACCORDING TO FDA

Medical devices are categorized by the FDA, the oldest consumer protection organization in the US, according to their intended use and medical specialty. In the end, the FDA assigns all of these devices to one of three classes (Classes I, II, and III) based on their risks.[1]

1) **Class I:** When compared to other classes, these devices have a simpler design. These are low-risk devices that only require the most basic protections to guarantee their functionality and safety. Since these devices do not present an unreasonable risk of disease or injury and are neither life-saving nor life-threatening, they are subject to basic regulations or none at all.[1] Class I devices include colostomy bags, oxygen masks, stethoscopes, and examination gloves.[3]
2) **Class II:** In contrast to the European Union medical device regulation, which is further divided into two classes: Class II-a, which includes medium-risk devices, and Class II-b, which includes medium-to-higher-risk devices, these devices are typically medium-risk devices and are composed of a single class. This class comprises 43 percent of medical devices.[1] Intensive care monitoring equipment, ventilators, blood transfusion tubes, catheters, and hearing aids are a few examples.[3] These devices are governed by both general and specific controls that must provide sufficient safety and effectiveness and explain how these controls achieve this.[1]
3) **Class III:** Class III devices are regarded as exceedingly hazardous. Examples include pacemakers, balloon catheters, prosthetic heart valves, and other medical devices.[3] To guarantee their safety and effectiveness, the most dangerous devices are put through several general and specific controls. This category includes 10% of the FDA-regulated medical devices. Prior to receiving a license, Class III devices must undergo premarket approval (PMA) and other crucial procedures. To prove their efficacy and safety, these devices must undergo a comprehensive clinical trial.[1]



Fig. Classification of medical devices according to the FDA.[4]

IMPORTANCE OF CLINICAL TRIALS IN MEDICAL DEVICES

- Clinical trials are the systematic assessment of a medical device's efficacy, safety, and performance in human participants. These assessments help determine whether a product meets the requirements and provides a significant advantage over rivals.[5]
- Volunteers for clinical trials were the first to take part in any new drug or therapy. Our current high standards of medical care are the result of earlier research administered by the US Food and Drug Administration (FDA).[6]
- The development and evaluation of medical devices depend on clinical trials. Because of these trials, which provide valuable information about the safety and effectiveness of new ideas, only the most reliable and beneficial devices make it to the market.[5]
- Before being approved for widespread use, these trials are meant to evaluate the efficacy and safety of new medical treatments, including drugs, medical devices, vaccines, and treatment methods.[7]
- The FDA works to protect people and ensure they have accurate information when they are thinking about attending a clinical trial.[6]
- Clinical trials are the foundation of evidence-based medicine. They provide doctors and other healthcare professionals with the knowledge they need to make informed decisions about the use of medical devices. Clinical trials meet the needs of patients and medical professionals by putting devices through real-world testing to ensure their safety and efficacy.[5]

DEEP BRAIN STIMULATION

A number of neurologic and neuropsychiatric conditions can be effectively treated with deep brain stimulation (DBS), which involves implanting electrodes into specific brain regions over time to deliver electrical stimulation. DBS is still a therapy that is not used enough, even with its safety and effectiveness.[8] With DBS, electrodes are positioned next to the brain's deep structures. A wire connects these electrodes to a pulse generator that is inserted subcutaneously into the chest wall. The electrodes are finally instructed to fire by the computer that controls the pulse generator. In addition to reviewing the interprofessional team's role in enhancing patient care for patients receiving deep brain stimulation, this activity explains how DBS is applied.[9] The FDA approved DBS for the treatment of epilepsy, essential tremor (ET), and Parkinson's disease (PD). It also granted Humanitarian Device Exemptions for the treatment of obsessive-

compulsive disorder (OCD) and dystonia.[8] The 1990s saw the first approval of deep brain stimulation (DBS) for the treatment of movement disorders. DBS may be able to provide symptom relief for a number of disease processes.[9] Few patients receive DBS, despite it being the standard of care for Parkinson's disease (PD) and other neurologic disorders. This might be a result of its intrusive nature, the high expense of treatment (including surgery and postoperative programming visits), and the patient's restricted access to specialized care. More lead contacts, more algorithms, more stimulation patterns, and the emergence of more treatment indications are examples of technological advancements.[8]

Fig. Deep brain stimulation.[10]

ANATOMY OF DBS

The deep brain stimulation (DBS) device is made up of electrodes that are inserted next to particular deep brain structures. These electrodes are then connected by a subcutaneous wire to a device that resembles a pacemaker (pulse generator) that is inserted into the chest wall. The pulse generator then receives the stimulation parameters—which include the appropriate amplitudes, frequencies, and pulse width—from a computer. DBS frequently targets the ventral intermediate nucleus of the thalamus (VIM), globus pallidus interna (GPi), and subthalamic nucleus (STN).[9] Two steps are usually required to insert the leads and neurostimulator:

1) Initially, the neurosurgeon inserts the leads into one or both sides of the brain; this is frequently done while the patient is conscious.
2) While the patient is asleep, a second procedure involves implanting a neurostimulator in the chest.

The neurosurgeon, neurologist, or primary care physician can program the neurostimulator to determine the best settings that work for each patient.[11]



Fig. Anatomy of DBS.[11]

KEY REGULATORY REQUIREMENTS FOR DBS CLINICAL TRIALS

Due to their classification as Class III (high-risk) medical devices, DBS devices are governed by stringent regulations in various jurisdictions.

A. FDA Regulation in the United States

- Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA of the United States regulates DBS devices and mandates Premarket Approval (PMA). Among the legal requirements are: Clinical trials involving DBS in human subjects require the following:

1. Investigational Device Exemption (IDE): Guarantees adherence to safety procedures and Good Clinical Practice (GCP), and needs approval from the Institutional Review Board (IRB).
2. Premarket Approval (PMA): Thorough clinical studies proving the safety and efficacy of DBS devices are required, which demands the submission of thorough clinical trial data as well as ongoing safety monitoring.
3. Post-Market Surveillance (PMS): Post-approval studies (PAS) are one way the FDA requires ongoing safety monitoring of DBS device systems for reporting medical devices (MDR).[12]

B. CE Marking and MDR Compliance in the European Union

- According to the Medical Device Regulation (EU MDR 2017/745), DBS devices are classified as Class III and must bear the CE Mark to be approved for sale in the EU.

1. Clinical Investigation Requirements: ISO 14155 (International Standard for Medical Device Clinical Investigations) must be followed during trials. Like the IRB in the US, ethics committee approval is required.
2. Evaluation of Conformance and CE Marking: Carried out to assess the data from clinical trials by a Notified Body (NB). Necessary to prove efficacy, safety, and quality assurance.
3. Post-Market Clinical Follow-up (PMCF): Continuous evaluation of the performance and safety of the device. Gathering empirical data from safety reports and registry studies.[13]

PROCEDURE FOR DEEP BRAIN STIMULATION (DBS) CLINICAL TRIAL APPROVAL

Before a device is put on the market, it must pass several stages of approval for DBS clinical trials to guarantee safety, effectiveness, and ethical compliance.

1) Pre-clinical Examination

- Before human trials, research in labs and on animals evaluates materials for electrodes that are biocompatible.
- Safety and device functionality in animal models.

2) Clinical Investigation Approval (EU) and FDA (USA) Investigational Device Exemption (IDE)

- Necessary before performing clinical trials on humans. Guarantees adherence to GCP, or good clinical practice.
- Requires approval from the Ethics Committee or Institutional Review Board (IRB).

3) Phases of Clinical Trials

- Phase I: A small study with 10–30 patients to assess safety and ideal stimulation conditions.
- Phase II: A medium-sized study with 50–200 participants that focuses on side effects and efficacy.
- Phase III: Extensive studies involving hundreds of patients to verify long-term safety and efficacy to obtain regulatory approval.

4) FDA/CE Mark Premarket Approval (PMA) in the EU

- Submitting thorough clinical trial data to the appropriate regulatory bodies.
- A risk-benefit analysis is done before final approval.

5) Post-Market Surveillance (PMS)

- Constant safety observation via adverse event reporting and patient registries.[14]

PROS AND CONS OF DEEP BRAIN STIMULATION

Pros of deep brain stimulation

1) Decrease in Adverse Symptoms: DBS frequently drastically lowers symptoms such as motor symptoms like stiffness, tremor, slowness, and dyskinesia. DBS has also been demonstrated to help with on/off fluctuations, enhance mood and quality of life, and boost vitality in general.
2) No Nerve Cells Must Be Removed: No nerve cells must be removed to perform DBS surgery. There is no brain damage from DBS.
3) Less Medication: DBS surgery helps reduce the major expense of medication, as well as the side effects of Levodopa.
4) Customized Care: As needed, doctors and the person with DBS can subjectively modify the electrodes, stimulation frequency, and intensity.
5) Independent Life: Patients who suffer from Parkinson's disease, tremor, any movement disorder, or dyskinesia are also dependent on others for everyday tasks. DBS surgery helps people manage their symptoms so they can take care of themselves.[15]

Cons of deep brain stimulation

1) Risk of Surgery or Surgical Side Effects: bleeding, stroke, infection, and fluid buildup in the brain are all risks associated with surgery. Furthermore, we are aware of the brain's complexity and sensitivity.
2) Expensive: The cost of the DBS procedure can range from $15,000 to $20,000, even though many insurance companies may cover all or part of it.
3) Results Are Not Immediate: Determining the ideal ratio of DBS stimulation to medication to manage symptoms will take months. While some symptoms might go away quickly, it might take you a long time to find the right combination for long-term effects.
4) Invasive and Awake during Procedure: Deep brain stimulation (DBS) surgery will require a scalp incision and access to deep brain regions. Furthermore, people are awake throughout the process, which some people may find frightening.
5) Potential Risks Associated with Specific Electronics: People with DBS can typically be around simple electronics, but larger, more potent devices, such as a total body coil MRI, might not be allowed after the procedure. (15)

FUTURE PROSPECTS OF DBS

A) Regulatory Development

- New Structures to Accelerate Innovative Medical Technology.
- Regulatory bodies are creating expedited approval processes for cutting-edge DBS systems, particularly those that use AI and closed-loop feedback (FDA, 2022).

- The FDA's Breakthrough Devices Program and comparable EU programs enable devices that address unmet clinical needs to be reviewed and approved more quickly.[12]

B) Developments in Technology

- Closed-loop (adaptive) DBS Systems: Conventional DBS systems provide constant stimulation within predetermined bounds. By using real-time neural feedback to modify stimulation in response to patient brain activity,
- Adaptive DBS (aDBS) systems improve treatment accuracy and minimize side effects.
- In Parkinson's disease and other neurological conditions, adaptive DBS enhances motor function and lowers the need for medication.[16]

C) AI-Powered Customized DBS Therapy

- In order to predict patient-specific responses and modify stimulation parameters appropriately, DBS systems are incorporating artificial intelligence (AI) and machine learning.
- It is anticipated that AI-powered DBS will enhance treatment results by gradually adjusting to each patient's unique neurophysiological changes.[16]



Fig. Development in Deep Brain Stimulation (DBS).[17]

CONCLUSION

One of the most promising neuromodulation treatments for treating complicated neurological and psychiatric conditions, including essential tremor, dystonia, and Parkinson's disease, is deep brain stimulation (DBS). The structured clinical trial process, which includes preclinical testing, phased clinical trials, and post-market surveillance, guarantees that DBS devices meet strict safety, efficacy, and regulatory standards despite their complexity and the invasive nature of the procedure. The FDA Premarket Approval (PMA), CE Mark certification, ISO 14155 compliance, and other regulatory frameworks that rigorously evaluate DBS devices emphasize the significance of clinical evidence in confirming safety and therapeutic efficacy. Significant technological developments, such as AI-driven personalized therapy and adaptive (closed-loop) DBS systems, are redefining the field of DBS and improving patient outcomes by increasing precision. Real-time stimulation parameter optimization through machine learning integration into DBS systems could improve treatment efficacy and minimize adverse effects. Long-term care and patient accessibility are

also being enhanced by the move toward decentralized trials and remote monitoring via wearable technology and telemedicine. With regulatory agencies launching fast-track programs for novel devices to address unmet clinical needs, the future of DBS clinical trials looks extremely bright. Advanced DBS systems should be approved more quickly thanks to the FDA's Breakthrough Devices Program and comparable EU initiatives, which will promote quick clinical translation. The creation of adaptive, AI-driven DBS systems will continue to transform the treatment of neurological and psychiatric conditions as interdisciplinary cooperation between neurosurgeons, neurologists, engineers, and data scientists grows. Eventually, more efficient, secure, and patient-centered treatment options will result from continuous developments in DBS technology, clinical trial design, and regulatory pathways.

REFERENCES

1. A review article by Felix A. Tettey-Engmann and Santosh Kumar Parupelli, on Biomedical Devices: Classification, Regulatory Guidelines, Human Factors, Software as a Medical Device, and Cybersecurity, from ResearchGate.
2. An article entitled An Overview of CDSCO Medical Devices Classification was published in May 2022 by Pharmadocx Consultants.
3. An article by Dr. Steven Patrick on Medical Devices and their Classification from the Journal of Biomedical Engineering and Medical Devices, 2022; 7(3).
4. An image from a blog on Why Medical Device Classification Matters? From Arena Solutions.
5. A Blog from LindusHealth on ‘The Importance of clinical trials for medical devices’ by Meri Beckwith.
6. An article by Jill M. Novitzke on 'The Significance of Clinical Trials', from the National Institute of Health (nih.gov).
7. An article by Walter Jager on ‘The Importance of Clinical Trials in Advancing Medical Research’ from Open Access Journals (openaccessjournal.com).
8. An article by Stephanie S. Sandoval-Pistorius and others on ‘Advances in Deep Brain Stimulation: From Mechanisms to Applications’ from The Journal of Neuroscience.
9. An article by Kamron A. Fariba and Vikas Gupta on 'Deep Brain Stimulation' from the National Library of Medicine (statpearls).
10. An image of Deep Brain Stimulation from a blog of Pacific Neuroscience Institute.
11. A Blog of ‘Deep Brain Stimulation: Relief from Movement Disorders’ from Michigan Head and Spine Institute.
12. U.S. Food and Drug Administration (FDA). (n.d.). *Premarket approval (PMA)*. U.S. Department of Health and Human Services. Retrieved August 6, 2025.
13. European Commission. (2017) ‘Regulation (EU) 2017/745 of the European Parliament and of the Council on medical devices’, Official Journal of the European Union, Retrieved August 6, 2025.
14. Hariz, M., & Blomstedt, P., ‘Deep brain stimulation: A paradigm shifting approach to treat neurological disorders’, Nature Reviews Neurology, 2022; 18(4): 221–234.
15. A Blog by Dr. Gurneet Singh Sawhney from ‘Pros and Cons of Deep Brain Stimulation’, on August 15, 2022.
16. Gilron, R., Little, S., Perrone, R., Wilt, R., & de Hemptinne, C., ‘Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease’, Nature Biotechnology, 2021; 39(9): 1078–1085.
17. An image from ‘Technology of Deep Brain Stimulation: current status and future directions’ by Joachim K. Krauss and others from ResearchGate.